Literature DB >> 18567579

Defective osteoclastogenesis by IKKbeta-null precursors is a result of receptor activator of NF-kappaB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation.

Jesse E Otero1, Simon Dai, Domenica Foglia, Muhammad Alhawagri, Jean Vacher, Manolis Pasparakis, Yousef Abu-Amer.   

Abstract

It has been reported previously that inhibitory kappaB kinase (IKK) supports osteoclastogenesis through NF-kappaB-mediated prevention of apoptosis. This finding suggests that the ligand for receptor activator of NF-kappaB (RANKL), the master osteoclastogenic cytokine, induces apoptosis of osteoclast precursors (OCPs) in the absence of IKKbeta/NF-kappaB competency. To validate this hypothesis, we sought to determine the pro-apoptotic signaling factors induced by RANKL in IKKbeta-null osteoclast OCPs and to rescue osteoclast differentiation in the absence of IKKbeta through their inhibition. To accomplish this, we generated mice that lack IKKbeta in multiple hematopoietic lineages, including OCPs. We found that these mice possess both in vitro and in vivo defects in osteoclast generation, in concurrence with previous reports, and that this defect is a result of susceptibility to RANKL-mediated apoptosis as a result of gain-of-function of JNK activation. We demonstrate that differentiation of OCPs depends on IKKbeta because reduced IKKbeta mRNA expression correlates with impaired induction of osteoclast differentiation markers in response to RANKL stimulation. We further show that fine-tuned inhibition of JNK activation in these cells inhibits RANKL-induced apoptosis and restores the ability of IKKbeta-null OCPs to become mature osteoclasts. Our data highlight the pro-osteoclastogenic and anti-apoptotic roles of IKKbeta in OCPs and identify a pro-apoptotic mechanism activated within the RANK signalosome.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18567579      PMCID: PMC2528995          DOI: 10.1074/jbc.M800434200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  29 in total

1.  Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway.

Authors:  U Senftleben; Y Cao; G Xiao; F R Greten; G Krähn; G Bonizzi; Y Chen; Y Hu; A Fong; S C Sun; M Karin
Journal:  Science       Date:  2001-08-24       Impact factor: 47.728

2.  MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases.

Authors:  A Theodosiou; A Smith; C Gillieron; S Arkinstall; A Ashworth
Journal:  Oncogene       Date:  1999-11-25       Impact factor: 9.867

Review 3.  Nuclear factor-kappaB activation: a question of life or death.

Authors:  Shishir Shishodia; Bharat B Aggarwal
Journal:  J Biochem Mol Biol       Date:  2002-01-31

Review 4.  Integrating cell-signalling pathways with NF-kappaB and IKK function.

Authors:  Neil D Perkins
Journal:  Nat Rev Mol Cell Biol       Date:  2007-01       Impact factor: 94.444

5.  Inhibition of JNK activation through NF-kappaB target genes.

Authors:  G Tang; Y Minemoto; B Dibling; N H Purcell; Z Li; M Karin; A Lin
Journal:  Nature       Date:  2001-11-15       Impact factor: 49.962

6.  Identification of the critical features of a small peptide inhibitor of JNK activity.

Authors:  Renae K Barr; Tulene S Kendrick; Marie A Bogoyevitch
Journal:  J Biol Chem       Date:  2002-01-14       Impact factor: 5.157

7.  JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms.

Authors:  Jean-Pierre David; Kanaga Sabapathy; Oskar Hoffmann; Maria H Idarraga; Erwin F Wagner
Journal:  J Cell Sci       Date:  2002-11-15       Impact factor: 5.285

8.  v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation.

Authors:  Seoung-Hoon Lee; Jaerang Rho; Daewon Jeong; Jai-Yoon Sul; Taesoo Kim; Nacksung Kim; Ju-Seob Kang; Takeshi Miyamoto; Toshio Suda; Sun-Kyeong Lee; Robert J Pignolo; Boguslawa Koczon-Jaremko; Joseph Lorenzo; Yongwon Choi
Journal:  Nat Med       Date:  2006-11-26       Impact factor: 53.440

9.  TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2.

Authors:  Manolis Pasparakis; Gilles Courtois; Martin Hafner; Marc Schmidt-Supprian; Arianna Nenci; Atiye Toksoy; Monika Krampert; Matthias Goebeler; Reinhard Gillitzer; Alain Israel; Thomas Krieg; Klaus Rajewsky; Ingo Haase
Journal:  Nature       Date:  2002-06-20       Impact factor: 49.962

10.  Dominant-negative IkappaB facilitates apoptosis of osteoclasts by tumor necrosis factor-alpha.

Authors:  Sabiha Abbas; Yousef Abu-Amer
Journal:  J Biol Chem       Date:  2003-03-11       Impact factor: 5.157

View more
  29 in total

1.  Tyrosine phosphorylation is required for IkappaB kinase-beta (IKKbeta) activation and function in osteoclastogenesis.

Authors:  Isra Darwech; Jesse E Otero; Muhammad A Alhawagri; Yousef Abu-Amer
Journal:  J Biol Chem       Date:  2010-06-09       Impact factor: 5.157

Review 2.  Role of NF-κB in the skeleton.

Authors:  Deborah Veis Novack
Journal:  Cell Res       Date:  2010-11-16       Impact factor: 25.617

3.  Neonatal High Bone Mass With First Mutation of the NF-κB Complex: Heterozygous De Novo Missense (p.Asp512Ser) RELA (Rela/p65).

Authors:  Anja L Frederiksen; Martin J Larsen; Klaus Brusgaard; Deborah V Novack; Peter Juel Thiis Knudsen; Henrik Daa Schrøder; Weimin Qiu; Christina Eckhardt; William H McAlister; Moustapha Kassem; Steven Mumm; Morten Frost; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2015-08-06       Impact factor: 6.741

4.  Targeting the NF-κB signaling pathway in chronic tendon disease.

Authors:  Adam C Abraham; Shivam A Shah; Mikhail Golman; Lee Song; Xiaoning Li; Iden Kurtaliaj; Moeed Akbar; Neal L Millar; Yousef Abu-Amer; Leesa M Galatz; Stavros Thomopoulos
Journal:  Sci Transl Med       Date:  2019-02-27       Impact factor: 17.956

Review 5.  RNA therapeutics targeting osteoclast-mediated excessive bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Adv Drug Deliv Rev       Date:  2011-09-10       Impact factor: 15.470

6.  Attenuation of NF-κB in Intestinal Epithelial Cells Is Sufficient to Mitigate the Bone Loss Comorbidity of Experimental Mouse Colitis.

Authors:  Ke Ke; Tim Hung-Po Chen; Manoj Arra; Gabriel Mbalaviele; Gaurav Swarnkar; Yousef Abu-Amer
Journal:  J Bone Miner Res       Date:  2019-07-25       Impact factor: 6.741

7.  Impediment of NEMO oligomerization inhibits osteoclastogenesis and osteolysis.

Authors:  Isra Darwech; Jesse Otero; Muhammad Alhawagri; Simon Dai; Yousef Abu-Amer
Journal:  J Cell Biochem       Date:  2009-12-15       Impact factor: 4.429

Review 8.  Inflammation, cancer, and bone loss.

Authors:  Yousef Abu-Amer
Journal:  Curr Opin Pharmacol       Date:  2009-07-02       Impact factor: 5.547

9.  Ubiquitin-like domain of IKKβ regulates osteoclastogenesis and osteolysis.

Authors:  Yanhong Zhang; Jesse E Otero; Yousef Abu-Amer
Journal:  Calcif Tissue Int       Date:  2013-05-18       Impact factor: 4.333

Review 10.  Cartilage homeostasis in health and rheumatic diseases.

Authors:  Mary B Goldring; Kenneth B Marcu
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.